The Use of Interleukin-22 as a Novel Marker of Disease Activity in Female Patients with Rheumatoid Arthritis

Yousef, Laila Mohamed; Aboalftoh, Sahar; Abdel-Latef, Tamer Mohamed; Ali, Khalid Elsayed

doi:10.21608/smj.2018.40904

The Use of Interleukin-22 as a Novel Marker of Disease Activity in Female Patients with Rheumatoid Arthritis

Document Type : Original Article

Authors

¹ Department of Clinical and Chemical pathology, Faculty of Medicine, Sohag University.

² Department of Clinical and Chemical pathology, Sohag Faculty of Medicine, Sohag University.

10.21608/smj.2018.40904

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by progressively destructive joint inflammation and destruction of articular cartilage, bone and synovial hyperplasia. Cytokines play a fundamental role in the processes that cause inflammation, articular destruction and extra-articular manifestations associated with RA.The preferential production of interleukin22 (IL22) by T cells suggests that elevated levels of this cytokine exist in chronic, T cell-mediated diseases, such as psoriasis and RA and that IL-22 plays an important role in the pathogenesis of these disorders.
Objective: To study the role of IL-22 in RA.
Methods:IL-22 serum levelswere measuredin55 female patients with RA, 28 of them on medical treatment and the other 27 were newly diagnosed patients and in 18 healthy controls. Patients are assessed for clinical and laboratory variables. Correlations of IL-22 serum levels with disease activity markers as disease activity score for 28 joints (DAS28), serological markers, bone erosions were assessed.
Results: IL-22 levels were increased in patients with RA compared with controls (mean 34.6 pg/ml and 3.2pg/ml, respectively; P < 0.001). Levels of IL-22 correlated positively with DAS28 score (P <0.001). C-reactive protein (CRP) correlated positivity with high levels of IL-22 in RA patients (mean 53.8 pg/ml; P < 0.001) and rheumatoid factor (RF) correlated positivity with high levels of IL-22 in RA patients (mean 46.1 pg/ml;P < 0.001). The presence of bone erosions was associated with high IL-22 levels (P = 0.008).
Conclusion:IL-22 is elevated in the serum of patients with RA.Elevated serum IL-22allows discrimination between patients with different clinical and laboratory measures and indicates thepotential of IL-22 as an additional tool for assessment of activity in RA, particularly in patients with RFantibodies. IL-22 is associated with bone destructive disease.

Keywords

References

1. Feldmann M., Brennan F.M., Maini R.N. (1996): Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397–440.

2. Tian J., Yong J., Dang H., Kaufman D.L. (2011):Oral gaba treatment downregulates inflammatory responses in amouse model of rheumatoid arthritis. Autoimmunity 44, 465–470.

3. Sakaguchi S., Benham H., Cope A.P., Thomas R. (2012):T-cell receptor signaling and the pathogenesis ofautoimmune arthritis: Insights from mouse and man. Immunol. Cell. Biol. 90, 277–287.

4. Choy E.H. and Panayi G.S. (2001):Cytokine pathways and joint inflammation in rheumatoid arthritis. Engl. J. Med.344, 907–916.

5. Linsley P.S. and Nadler S.G. (2009):The clinical utility of inhibiting cd28-mediated costimulation. Immunol. Rev. 229, 307–321.

6. Sprent J. and Surh C.D. (2011):Normal t cell homeostasis: The conversion of naive cells into memory-phenotype cells.Nat. Immunol. 12, 478–484.

7. Devergne O., Hummel M., Koeppen H., Le Beau M.M., Nathanson E.C., Kieff E., Birkenbach M. (1996):A novelinterleukin-12 p40-related protein induced by latent epstein-barr virus infection in b lymphocytes. J. Virol. 70, 1143–1153.

8. Wolk K. and Sabat R. (2006):Interleukin-22: A novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev;17:367-80..

9.Zenewicz L.A. and Flavell R.A. (2011):Recent advances in IL-22 biology. Int Immunol. 23:159-63.

10. Xie M.H., Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, et al. (2000):Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 275:31335-9.

11.Kotenko S.V., Izotova L.S., Mirochnitchenko O.V., Esterova E., Dickensheets H, Donnelly RP, et al. (2001):Identification of the functional interleukin-22 (IL-22) receptor complex: The IL-10R2 chainIL-10R-beta) is a common chain of both the IL-10 and IL-22IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 276:2725 32.

12. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. (2006):Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203:2271-9.

13. Andoh A., Zhang Z., Inatomi O., Fujino S., Deguchi Y., Araki Y., et al. (2005):Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129:969-84.

14. Ikeuchi H., Kuroiwa T., Hiramatsu N., Kaneko Y., Hiromura K., Ueki K., et al. (2005):Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis Rheum 52:1037-46.

15. Leipe J., Schramm M.A., Grunke M., Baeuerle M., Dechant C., Nigg A.P., et al. (2011):Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Ann Rheum Dis 70:1453-7.

16. Shen H., Goodall J.C. and Hill Gaston J.S. (2009):Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 60:1647-56.

17. Shen H., Goodall J.C. and Gaston J.S. (2010):Frequency and phenotype of T helper 17 cells in peripheral blood and synovial fluid of patients with reactive arthritis. J Rheumatol;37:2096-9.

18. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K. and Sabat R. (2004):IL-22 increases the innate immunity of tissues. Immunity 21:241-54.

19. Lavoie T.N., Stewart C.M., Berg K.M., Li Y., Nguyen C.Q. (2011):Expression of interleukin-22 in Sjogren’s syndrome: Significant correlation with disease parameters. Scand J Immunol 74:377-82.

20. Cascao R., Moura R.A., Perpetuo I., Canhao H., Vieira-Sousa E., Mourao A.F., et al. (2010):Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther 12:R196.

21. Aletaha D., Neogi T., Silman A.J. et al. (2010): Rheumatoid arthritis classification criteria: An American Colleague of Rheumatology/European League against Rheumatism Collaborative initiative. Arthritis and Rheumatism, 62, 2569-2581

22. Prevoo M.L., van’t Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., and van Riel P.L :(1995).Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum; 38:44-8.

23.Westergren (1991): Studies of the suspension stability of blood in pulmonary tuberculosis. Acta Medica; 54: 247.

24.Fisher C.L., Nakamura R. and Amr J. (1976): laboratory medicine immunology. Immunol; 20 (6) 12 – 15.

25.Heller G., Jacobson S., Koloday M. et al., (1954): The determination of rheumatoid factor. Immunol; 6 (1): 46 – 50.

26.Coenen D., Verschueren P., Westhovens R. and Bossuyt X. (2007): Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem; 53(3):498-504.

27. Larsen A. (1995): How to apply Larsen Score in evaluating radiographs of rheumatoid arthritis in long term studies? J Rheumatol. 22: 1974-1975.

28. Piccoli A.K., Alegretti A.P., Schneider L., Schmidt P.L. and Xavier R.M. (2011):Expression of complement regulatory proteins CD55, CD59, CD35, and CD46 in rheumatoid arthritis. Rev Bras Reumatol; 51(5):497-510

29. Liu F.L., Chen C.H., Chu S.J., Chen J.H., Lai J.H. Sytwu H.K. and Chang D.M. (2007): Interleukin (IL)-23 p19 expression induced by IL-1beta in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-kappaB and AP-1 dependent pathway. Rheumatology (Oxford). 46: 1266–1273.

30.Wolk K., Witte E., Witte K., Warszawska K. and Sabat R. (2010): Biology of interleukin-22, Semin Immunopathol 32:17–31.

31. Rocha Jr L.F., Duarte A.L., Dantas A.T., Mariz H.A., Pitta I.D., Galdino S.L., et al. (2012): Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. Journal of Rheumatology; 39; 1320-1325.

32. Egila. S., Osama S., Emtethal A.S. and Shimaa H.M. (2014): Serum IL-22 in rheumatoid arthritis patients; Page 81 – 96

33. Zhang L., J. M. Li, X.G. Liu, et al. (2011): Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J. Clin. Immunol. 31: 606–614.

34. Pan Hai-Feng, Xiang-Pei Li, Song Guo Zheng and Dong-Qing Y (2013): Emerging role of interleukin-22 in autoimmune diseases Cytokine & Growth Factor Reviews. 24: 51–57.